drugset / Trial / NCT01132625

Dose Escalation Study of AUY922 in Advanced Solid Malignancies in Japan

NCT01132625

Phase 1 Completed 37 enrolled Novartis Pharmaceuticals
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study will characterize the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of AUY922 in adult patients with advanced solid malignancies in Japan.

Timeline

Start
2008-11
Primary completion
2012-05
Completion
2012-05

Drugs

EvaluationDrugModalityDoseRoute
Subject AUY922 Small molecule Intravenous

Indications